SlideShare a Scribd company logo
1 of 23
Download to read offline
Local Advanced Esophageal Cancer
(T3-4N0-2M0): Artificial Intelligence,
Synergistics, Complex System Analysis and
Simulation of Alive Supersystems for Best
Management.
Kshivets Oleg Surgery Department, Bagrationovsk Hospital,
Bagrationovsk, Kaliningrad, Russia
ABSTRACT
OBJECTIVE: The survival of patients with local advanced of esophageal cancer (EC) takes several months. Radical operations are extremely
complex and remain the prerogative of several best thoracoabdominal surgeons of the world. The search of optimal treatment plan for EC patients
(ECP) with stage T3-4N0-2M0 was realized. We examined factors in terms of precise prediction of 5-year survival (5YS) of local advanced ECP after
complete (R0) combined esophagogastrectomies (E).
METHODS: We analyzed data of 313 consecutive ECP (age=56.2±9 years; tumor size=8.1±2.8 cm) radically operated and monitored in 1975-2024
(m=233, f=80; Lewis=122, Garlock=191, combined E with resection of trachea, bronchus, lung, aorta, VCS, pericardium, liver, pancreas, diaphragm,
colon, splenectomy=170; only surgery-S=217, adjuvant chemoimmunoradiotherapy-AT=96: 5FU+thymalin/taktivin +radiotherapy 45-50Gy; T3=185,
T4=128; N0=96, N1=38, N2=179, M0=313; G1=71, G2=57, G3=185; squamous=109, adenocarcinoma=194, mix=10. Variables selected for 5YS study were
input levels of 45 blood parameters, sex, age, TNMG, cell type, tumor size. Survival curves were estimated by the Kaplan-Meier method. Differences in
curves between groups of ECP were evaluated using a log-rank test. Multivariate Cox modeling, multi-factor clustering, discriminant analysis, structural
equation modeling, Monte Carlo, bootstrap, synergetics simulation and neural networks computing were used to determine any significant dependence.
RESULTS: Overall life span (LS) was 1243.6±1691.4 days and cumulative 5YS reached 29%, 10 years – 19.2%, 20 years – 13.3%. 55 ECP lived more
than 5 years (LS=4199.4±2295.3 days), 25 – more than 10 years (LS=6256.3±1884.8 days). 186 ECP died because of EC (LS=605.1±289.9 days). AT
significantly improved 5YS (56.8% vs. 22%) (P=0.0000). Cox modeling displayed that 5YS of ECP significantly depended on: Phase Transition N0-N12 in
terms of synergetics, G1-3, histology, AT, age, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), ESS,
prothrombin index, hemorrhage time, protein, residual nitrogen (P=0.000-0.033). Neural networks, genetic algorithm selection and bootstrap simulation
revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (2), healthy cells/CC (3), erythrocytes/CC (4), segmented neutrophils/CC (5),
eosinophils/CC (6), monocytes/CC (7), stick neutrophils/CC (8), lymphocytes/CC (9), leucocytes/CC (10). Correct prediction of 5YS was 100% by neural
networks computing.
CONCLUSIONS: 5YS of local advanced ECP after combined radical procedures significantly depended on: tumor characteristics, blood cell circuit,
cell ratio factors, biochemical factors, hemostasis system, anthropometric data and adjuvant treatment. Optimal strategies for local advanced ECP are:
1) availability of very experienced thoracoabdominal surgeons because of complexity radical procedures; 2) aggressive en block surgery and adequate
lymph node dissection for completeness; 3) precise prediction; 4) AT for ECP with unfavorable prognosis.
Data:
• Males…………………………………………………...233
• Females………..……………………………................80
• Age=56.2±9 years
• Tumor Size=8.1±2.8 cm
• Only Surgery.……………………………………........217
• Adjuvant Chemoimmunoradiotherapy
• (5FU+thymalin/taktivin, 5-6 cycles+ Radiotherapy
• 45-50Gy)………………………....................................96
:Radical Procedures
• Esophagogastrectomies Lewis (R0)…………………122
• Esophagogastrectomies Garlock (R0)………...........191
• Combined Esophagogastrectomies with Resection
• of Pancreas, Liver, Trachea, Lung, Aorta, Vena
• Cava Superior, Colon Transversum, Diaphragm,
Pericardium, Splenectomy (R0)……………...............170
• 2-Field Lymphadenectomy…………………………….186
• 3-Field Lymphadenectomy.………………………….…127
Staging:
• T3……186 N0..…...96 G1………….71
• T4……128 N1….....38 G2………….57
• M0…..313 N2…....179 G3…………185
• Adenocarcinoma…………………………….194
• Squamos Cell Carcinoma…………………..110
• Mix………………….....…………………...........10
Survival Rate:
• Alive………………………………………......105 (33.5%)
• 5-Year Survivors…………..…………..……..55 (17.6%)
• 10-Year Survivors…………………………....25 (8%)
• Losses………………………………………..186 (59.4%)
• General Life Span=1243.6±1691.4 days
• For 5-Year Survivors=4199.4±2295.3 days
• For 10-Year Survivors=6256.3±1884.8 days
• For Losses=605.1±289.9 days
• Cumulative 5-Year Survival……………………….29%
• Cumulative 10-Year Survival…………………......19.2%
• Cumulative 20-Year Survival…………………......13.3%
General Esophageal Cancer Patients (T3-4)
Survival after Complete
Esophagogastrectomies (Kaplan-Meier)
(n=313):
Survival Function
5YS=29%; 10YS=19.2%; 20YS=13.3%
Complete Censored
-5 0 5 10 15 20 25 30 35
Years after Esophagogastrectomies
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
Cumulative
Proportion
Surviving
Results of Univariate Analysis of Phase
Transition N0—N1-2 in Prediction of
Esophageal Cancer Patients (T3-4) Survival
(n=313):
Cumulative Proportion Surviving (Kaplan-Meier)
P=0.00354
Complete Censored
0 5 10 15 20 25 30 35
Years after Esophagogastrectomies
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
N0
N1-2
Results of Univariate Analysis of
Localization
(Cardioesophageal vs. Esophageal) in
Prediction of Esophageal Cancer
Patients (T3-4) Survival (n=313): Cumulative Proportion Surviving (Kaplan-Meier)
P=0.00109
Complete Censored
0 5 10 15 20 25 30 35
Years after Esophagogasrectomies
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
Esophageal Cancer Patients
Cardioesophageal Cancer Patients
Results of Univariate Analysis of Adjuvant
Treatment (Adjuvant
Chemoimmunoradiotherapy vs Surgery
along) in Prediction of Esophageal
Cancer Patients (T3-4) Survival (n=313):
Cumulative Proportion Surviving (Kaplan-Meier)
P=0.0000
Complete Censored
0 5 10 15 20 25 30 35
Years after Esophagogastrectomies
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
only Surgery
Adjuvant Chemoimmunoradiotherapy
Results of Cox Regression Modeling in
Prediction of Esophageal Cancer Patients
(T3-4) Survival after Complete
Esophagogastrectomies (n=313):
Cox Regression, ECP (T3-4N0-2), n=313
Parameter
Estimate
Standard
Error
Chi-square P value
95% Lower
CL
95% Upper
CL
Eosinophils (%) 1.450 0.63707 5.17929 0.022858 0.201 2.698
Stick Neutrophils (%) 1.594 0.64188 6.16669 0.013018 0.336 2.852
Segmented Neutrophils (%) 1.616 0.63118 6.55406 0.010465 0.379 2.853
Lymphocytes (%) 1.640 0.63515 6.66400 0.009838 0.395 2.884
Monocytes (%) 1.717 0.64700 7.04410 0.007953 0.449 2.985
ESS -0.017 0.00751 5.03756 0.024803 -0.032 -0.002
Hemorrhage Time 0.001 0.00047 4.52166 0.033468 0.000 0.002
Residual Nitrogen 0.058 0.01241 22.03938 0.000003 0.034 0.083
Protein 0.032 0.01054 8.96255 0.002756 0.011 0.052
Prothrombin Index 0.038 0.00802 22.68268 0.000002 0.022 0.054
Phase Transition N0---N12 0.513 0.19200 7.13876 0.007544 0.137 0.889
Age 0.031 0.01019 9.40805 0.002160 0.011 0.051
Histology -0.444 0.15086 8.65327 0.003265 -0.739 -0.148
G1-3 0.282 0.10138 7.76029 0.005341 0.084 0.481
Leucocytes (tot) 22.981 4.89333 22.05549 0.000003 13.390 32.571
Eosinophils (tot) -22.335 4.85003 21.20792 0.000004 -31.841 -12.829
Stick Neutrophils (tot) -22.207 4.86970 20.79526 0.000005 -31.751 -12.662
Lymphocytes (tot) -23.049 4.93130 21.84678 0.000003 -32.714 -13.384
Segmented Neutrophils (tot) -23.024 4.88779 22.18959 0.000002 -32.604 -13.444
Monocytes (tot) -23.043 4.86741 22.41275 0.000002 -32.583 -13.503
Leucocytes/Cancer Cells -157.315 28.43656 30.60461 0.000000 -213.050 -101.581
Eosinophils/Cancer Cells 156.586 28.69089 29.78630 0.000000 100.353 212.819
Segmented Neutrophils/Cancer Cells 157.829 28.43487 30.80849 0.000000 102.098 213.560
Stick Neutrophils/Cancer Cells 153.093 28.44108 28.97477 0.000000 97.350 208.837
Lymphocytes/Cancer Cells 156.884 28.52403 30.25085 0.000000 100.978 212.790
Monocytes/Cancer Cells 155.948 28.15775 30.67366 0.000000 100.760 211.136
Esophageal/Cardioesophageal Cancer 0.440 0.17284 6.47954 0.010912 0.101 0.779
Adjuvant Chemoimmunoradiotherapy -0.874 0.21985 15.81752 0.000070 -1.305 -0.4435
Results of Neural Networks and Monte Carlo
Computing in Prediction of Esophageal Cancer
Patients (T3-4) Survival after Complete
Esophagogastrectomies (n=241):
Corect Classification Rate=100%
Error=0.000
Area under ROC Curve=1.000
Neural Networks: Baseline Error=0.000
Area under ROC Curve=1.000; Correct
Classification Rate=100%; n=241
Rank Sensitivity
Phase Transition N0---N12 1 701
Eosinophils/Cancer Cells 2 491
Stick Neutrophils/Cancer Cells 3 269
Healthy Cells/Cancer Cells 4 176
Erythrocytes/Cancer Cells 5 175
Monocytes/Cancer Cells 6 151
Lymphocytes/Cancer Cells 7 124
Thrombocytes/Cancer Cells 8 100
Segmented Neutrophils/Cancer Cells 9 30
Leucocytes/Cancer Cells 10 24
Results of Bootstrap Simulation in Prediction
of Esophageal Cancer Patients Survival (T3-4)
after Complete Esophagogastrectomies (n=241):
Bootstrap Simulation:
Number of Samples=3333
Rank Kendall
Tau
P<
Hemorrhage Time 1 -0.171 0.05
Blood Chlorides 2 0.171 0.05
Esophageal/Cardioesophageal Cancer 3 -0.151 0.05
Prothrombin Index 4 -0.146 0.05
Phase Transition N0---N12 5 -0.144 0.05
Protein 6 -0.142 0.05
Results of Kohonen Self-Organizing
Neural Networks Computing in
Prediction of Esophageal Cancer Patients (T3-4) Survival after Complete Esophagogastrectomies
(n=241):
Esophageal Cancer Cell Dynamics:
Prognostic Equation Models of
Esophageal Cancer Patients (T3-4)
Survival after Complete
Esophagogastrectomies (n=241):
Prognostic Equation Models of
Esophageal Cancer Patients (T3-4)
Survival after Complete
Esophagogastrectomies (n=241):
Prognostic Equation Models of
Esophageal Cancer Patients (T3-4)
Survival after Complete
Esophagogastrectomies (n=241):
Prognostic Equation Models of
Esophageal Cancer Patients (T3-4)
Survival after Complete
Esophagogastrectomies (n=241):
SEPATH Modeling in Prediction of
Esophageal Cancer Patients (T3-4)
Survival after Complete
Esophagogastrectomies (n=241):
5-year survival of ECP after radical
procedures significantly depended on:
1) PT N0--N12;
2) Cell Ratio Factors;
3) Blood Cell Circuit;
4) Biochemical Factors;
5) Hemostasis System;
6) Adjuvant Treatment;
7) EC Characteristics;
8) EC Cell Dynamics;
9) Tumor Localization;
10) Anthropometric Data;
11) Surgery Type.
Conclusion:
Optimal treatment strategies for
local advanced ECP (T3-4) are:
1) Availability of Sufficient
Quantity of Very Experienced
Thoracoabdominal Surgeons
because of Extreme Complexity of
Radical Procedures;
2) Aggressive en block Combined
Surgery and Adequate Lymph
Node Dissection for
Completeness;
3) Precise Prediction;
4) Adjuvant
Chemoimmunoradiotherapy for
ECP with Unfavorable Prognosis.
Conclusion:
Address:
Oleg Kshivets,
M.D.,Ph.D.
Consultant Thoracic, Abdominal,
General Surgeon & Surgical
Oncologist
• e-mail: okshivets@yahoo.com
• skype: okshivets
• http: //www.ctsnet.org/home/okshivets

More Related Content

Similar to Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Synergistics, Complex System Analysis and Simulation of Alive Supersystems for Best Management.

Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction
Oleg Kshivets
 
• Gastric cancer prognosis and cell ratio factors
•	Gastric cancer prognosis and cell ratio factors           •	Gastric cancer prognosis and cell ratio factors
• Gastric cancer prognosis and cell ratio factors
Oleg Kshivets
 
Lung Cancer: Precise Prediction
Lung Cancer: Precise PredictionLung Cancer: Precise Prediction
Lung Cancer: Precise Prediction
Oleg Kshivets
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
Oleg Kshivets
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
Oleg Kshivets
 

Similar to Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Synergistics, Complex System Analysis and Simulation of Alive Supersystems for Best Management. (20)

KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
Kshivets milan2014
Kshivets milan2014Kshivets milan2014
Kshivets milan2014
 
Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020
 
Kshivets barcelona2016
Kshivets barcelona2016Kshivets barcelona2016
Kshivets barcelona2016
 
Kshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfKshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdf
 
Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction
 
Kshivets O. Gastric Cancer Relapse Surgery
Kshivets O. Gastric Cancer Relapse SurgeryKshivets O. Gastric Cancer Relapse Surgery
Kshivets O. Gastric Cancer Relapse Surgery
 
Kshivets iaslc denver2021
Kshivets iaslc denver2021Kshivets iaslc denver2021
Kshivets iaslc denver2021
 
• Gastric cancer prognosis and cell ratio factors
•	Gastric cancer prognosis and cell ratio factors           •	Gastric cancer prognosis and cell ratio factors
• Gastric cancer prognosis and cell ratio factors
 
Kshivets eacts milan2018
Kshivets eacts milan2018Kshivets eacts milan2018
Kshivets eacts milan2018
 
Kshivets sso2013
Kshivets sso2013Kshivets sso2013
Kshivets sso2013
 
Kshivets ny2021aats
Kshivets ny2021aatsKshivets ny2021aats
Kshivets ny2021aats
 
Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery
 
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryKshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
 
Kshivets wscts2019 sofia
Kshivets wscts2019 sofiaKshivets wscts2019 sofia
Kshivets wscts2019 sofia
 
Kshivets wscts2015
Kshivets wscts2015Kshivets wscts2015
Kshivets wscts2015
 
Kshivets O. Lung Cancer Stage III Surgery
Kshivets O. Lung Cancer Stage III Surgery Kshivets O. Lung Cancer Stage III Surgery
Kshivets O. Lung Cancer Stage III Surgery
 
Lung Cancer: Precise Prediction
Lung Cancer: Precise PredictionLung Cancer: Precise Prediction
Lung Cancer: Precise Prediction
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
 

More from Oleg Kshivets

Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Oleg Kshivets
 
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Oleg Kshivets
 
Kshivets iaslc singapore2020
Kshivets iaslc singapore2020Kshivets iaslc singapore2020
Kshivets iaslc singapore2020
Oleg Kshivets
 

More from Oleg Kshivets (15)

Kshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdf
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdf
 
Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdf
 
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
 
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
 
Kshivets elcc2022
Kshivets elcc2022Kshivets elcc2022
Kshivets elcc2022
 
Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659
 
Kshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarr
 
Kshivets eso10 y2021
Kshivets eso10 y2021Kshivets eso10 y2021
Kshivets eso10 y2021
 
Kshivets esmo2021
Kshivets esmo2021Kshivets esmo2021
Kshivets esmo2021
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets
 
Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival
 
Kshivets iaslc singapore2020
Kshivets iaslc singapore2020Kshivets iaslc singapore2020
Kshivets iaslc singapore2020
 
Kshivets barcelona2020
Kshivets barcelona2020Kshivets barcelona2020
Kshivets barcelona2020
 
Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020
 

Recently uploaded

Contact Now +9316020077 Call Girl In Goa By Goa ✂️ Call Girl Hotel With 100 ...
Contact Now  +9316020077 Call Girl In Goa By Goa ✂️ Call Girl Hotel With 100 ...Contact Now  +9316020077 Call Girl In Goa By Goa ✂️ Call Girl Hotel With 100 ...
Contact Now +9316020077 Call Girl In Goa By Goa ✂️ Call Girl Hotel With 100 ...
Real Sex Provide In Goa
 
ITM HOSPITAL The hospital has also been recognised as the best emerging hosp...
ITM  HOSPITAL The hospital has also been recognised as the best emerging hosp...ITM  HOSPITAL The hospital has also been recognised as the best emerging hosp...
ITM HOSPITAL The hospital has also been recognised as the best emerging hosp...
jvomprakash
 
Spauldings classification ppt by Dr C P PRINCE
Spauldings classification ppt by Dr C P PRINCESpauldings classification ppt by Dr C P PRINCE
Spauldings classification ppt by Dr C P PRINCE
DR.PRINCE C P
 
OBAT PENGGUGUR KANDUNGAN 081466799220 PIL ABORSI CYTOTEC PELUNTUR JANIN
OBAT PENGGUGUR KANDUNGAN 081466799220 PIL ABORSI CYTOTEC PELUNTUR JANINOBAT PENGGUGUR KANDUNGAN 081466799220 PIL ABORSI CYTOTEC PELUNTUR JANIN
OBAT PENGGUGUR KANDUNGAN 081466799220 PIL ABORSI CYTOTEC PELUNTUR JANIN
JUAL OBAT GASTRUL MISOPROSTOL 081466799220 PIL ABORSI CYTOTEC 1 2 3 4 5 6 7 BULAN TERPERCAYA
 
Goa Call Girl 931~602~0077 Call ✂️ Girl Service Vip Top Model Safe
Goa Call Girl  931~602~0077 Call ✂️ Girl Service Vip Top Model SafeGoa Call Girl  931~602~0077 Call ✂️ Girl Service Vip Top Model Safe
Goa Call Girl 931~602~0077 Call ✂️ Girl Service Vip Top Model Safe
Real Sex Provide In Goa
 
@Safe Abortion pills IN Jeddah(+918133066128) Un_wanted kit Buy Jeddah
@Safe Abortion pills IN Jeddah(+918133066128) Un_wanted kit Buy Jeddah@Safe Abortion pills IN Jeddah(+918133066128) Un_wanted kit Buy Jeddah
@Safe Abortion pills IN Jeddah(+918133066128) Un_wanted kit Buy Jeddah
Abortion pills in Kuwait Cytotec pills in Kuwait
 
TIME FOR ACTION: MAY 2024 Securing A Strong Nursing Workforce for North Carolina
TIME FOR ACTION: MAY 2024 Securing A Strong Nursing Workforce for North CarolinaTIME FOR ACTION: MAY 2024 Securing A Strong Nursing Workforce for North Carolina
TIME FOR ACTION: MAY 2024 Securing A Strong Nursing Workforce for North Carolina
Mebane Rash
 
Independent Call Girl in 😋 Goa +9316020077 Goa Call Girl
Independent Call Girl in 😋 Goa  +9316020077 Goa Call GirlIndependent Call Girl in 😋 Goa  +9316020077 Goa Call Girl
Independent Call Girl in 😋 Goa +9316020077 Goa Call Girl
Real Sex Provide In Goa
 
Obat aborsi Jakarta Timur Wa 081225888346 Jual Obat aborsi Cytotec asli Di Ja...
Obat aborsi Jakarta Timur Wa 081225888346 Jual Obat aborsi Cytotec asli Di Ja...Obat aborsi Jakarta Timur Wa 081225888346 Jual Obat aborsi Cytotec asli Di Ja...
Obat aborsi Jakarta Timur Wa 081225888346 Jual Obat aborsi Cytotec asli Di Ja...
icha27638
 
❤️ Chandigarh Call Girls ☎️99158-51334☎️ Escort service in Chandigarh ☎️ Chan...
❤️ Chandigarh Call Girls ☎️99158-51334☎️ Escort service in Chandigarh ☎️ Chan...❤️ Chandigarh Call Girls ☎️99158-51334☎️ Escort service in Chandigarh ☎️ Chan...
❤️ Chandigarh Call Girls ☎️99158-51334☎️ Escort service in Chandigarh ☎️ Chan...
rajveerescorts2022
 
❤️ Chandigarh Call Girls Service ☎️99158-51334☎️ Escort service in Chandigarh...
❤️ Chandigarh Call Girls Service ☎️99158-51334☎️ Escort service in Chandigarh...❤️ Chandigarh Call Girls Service ☎️99158-51334☎️ Escort service in Chandigarh...
❤️ Chandigarh Call Girls Service ☎️99158-51334☎️ Escort service in Chandigarh...
rajveerescorts2022
 
Pathways to Equality: The Role of Men and Women in Gender Equity
Pathways to Equality:          The Role of Men and Women in Gender EquityPathways to Equality:          The Role of Men and Women in Gender Equity
Pathways to Equality: The Role of Men and Women in Gender Equity
Atharv Kurhade
 
Goa Call Girl 931~602~0077 Call ✂️ Girl Service Vip Top Model Safe
Goa Call Girl  931~602~0077 Call ✂️ Girl Service Vip Top Model SafeGoa Call Girl  931~602~0077 Call ✂️ Girl Service Vip Top Model Safe
Goa Call Girl 931~602~0077 Call ✂️ Girl Service Vip Top Model Safe
Real Sex Provide In Goa
 

Recently uploaded (20)

ISO 15189 2022 standards for laboratory quality and competence
ISO 15189 2022 standards for laboratory quality and competenceISO 15189 2022 standards for laboratory quality and competence
ISO 15189 2022 standards for laboratory quality and competence
 
Contact Now +9316020077 Call Girl In Goa By Goa ✂️ Call Girl Hotel With 100 ...
Contact Now  +9316020077 Call Girl In Goa By Goa ✂️ Call Girl Hotel With 100 ...Contact Now  +9316020077 Call Girl In Goa By Goa ✂️ Call Girl Hotel With 100 ...
Contact Now +9316020077 Call Girl In Goa By Goa ✂️ Call Girl Hotel With 100 ...
 
ITM HOSPITAL The hospital has also been recognised as the best emerging hosp...
ITM  HOSPITAL The hospital has also been recognised as the best emerging hosp...ITM  HOSPITAL The hospital has also been recognised as the best emerging hosp...
ITM HOSPITAL The hospital has also been recognised as the best emerging hosp...
 
Post marketing surveillance in Japan, legislation and.pptx
Post marketing surveillance in Japan, legislation and.pptxPost marketing surveillance in Japan, legislation and.pptx
Post marketing surveillance in Japan, legislation and.pptx
 
Spauldings classification ppt by Dr C P PRINCE
Spauldings classification ppt by Dr C P PRINCESpauldings classification ppt by Dr C P PRINCE
Spauldings classification ppt by Dr C P PRINCE
 
OBAT PENGGUGUR KANDUNGAN 081466799220 PIL ABORSI CYTOTEC PELUNTUR JANIN
OBAT PENGGUGUR KANDUNGAN 081466799220 PIL ABORSI CYTOTEC PELUNTUR JANINOBAT PENGGUGUR KANDUNGAN 081466799220 PIL ABORSI CYTOTEC PELUNTUR JANIN
OBAT PENGGUGUR KANDUNGAN 081466799220 PIL ABORSI CYTOTEC PELUNTUR JANIN
 
Coach Dan Quinn Commanders Feather T Shirts
Coach Dan Quinn Commanders Feather T ShirtsCoach Dan Quinn Commanders Feather T Shirts
Coach Dan Quinn Commanders Feather T Shirts
 
VIP ℂall Girls Bodakdev Ahmedabad 7427069034 WhatsApp: Me All Time Serviℂe Av...
VIP ℂall Girls Bodakdev Ahmedabad 7427069034 WhatsApp: Me All Time Serviℂe Av...VIP ℂall Girls Bodakdev Ahmedabad 7427069034 WhatsApp: Me All Time Serviℂe Av...
VIP ℂall Girls Bodakdev Ahmedabad 7427069034 WhatsApp: Me All Time Serviℂe Av...
 
Nursing Care Plan for Surgery (Risk for Infection)
Nursing Care Plan for Surgery (Risk for Infection)Nursing Care Plan for Surgery (Risk for Infection)
Nursing Care Plan for Surgery (Risk for Infection)
 
Goa Call Girl 931~602~0077 Call ✂️ Girl Service Vip Top Model Safe
Goa Call Girl  931~602~0077 Call ✂️ Girl Service Vip Top Model SafeGoa Call Girl  931~602~0077 Call ✂️ Girl Service Vip Top Model Safe
Goa Call Girl 931~602~0077 Call ✂️ Girl Service Vip Top Model Safe
 
@Safe Abortion pills IN Jeddah(+918133066128) Un_wanted kit Buy Jeddah
@Safe Abortion pills IN Jeddah(+918133066128) Un_wanted kit Buy Jeddah@Safe Abortion pills IN Jeddah(+918133066128) Un_wanted kit Buy Jeddah
@Safe Abortion pills IN Jeddah(+918133066128) Un_wanted kit Buy Jeddah
 
Oral Sex ℂall Girls Gwalior Book Riya 7427069034 Top Class ℂall Girl Serviℂe ...
Oral Sex ℂall Girls Gwalior Book Riya 7427069034 Top Class ℂall Girl Serviℂe ...Oral Sex ℂall Girls Gwalior Book Riya 7427069034 Top Class ℂall Girl Serviℂe ...
Oral Sex ℂall Girls Gwalior Book Riya 7427069034 Top Class ℂall Girl Serviℂe ...
 
TIME FOR ACTION: MAY 2024 Securing A Strong Nursing Workforce for North Carolina
TIME FOR ACTION: MAY 2024 Securing A Strong Nursing Workforce for North CarolinaTIME FOR ACTION: MAY 2024 Securing A Strong Nursing Workforce for North Carolina
TIME FOR ACTION: MAY 2024 Securing A Strong Nursing Workforce for North Carolina
 
Independent Call Girl in 😋 Goa +9316020077 Goa Call Girl
Independent Call Girl in 😋 Goa  +9316020077 Goa Call GirlIndependent Call Girl in 😋 Goa  +9316020077 Goa Call Girl
Independent Call Girl in 😋 Goa +9316020077 Goa Call Girl
 
Obat aborsi Jakarta Timur Wa 081225888346 Jual Obat aborsi Cytotec asli Di Ja...
Obat aborsi Jakarta Timur Wa 081225888346 Jual Obat aborsi Cytotec asli Di Ja...Obat aborsi Jakarta Timur Wa 081225888346 Jual Obat aborsi Cytotec asli Di Ja...
Obat aborsi Jakarta Timur Wa 081225888346 Jual Obat aborsi Cytotec asli Di Ja...
 
❤️ Chandigarh Call Girls ☎️99158-51334☎️ Escort service in Chandigarh ☎️ Chan...
❤️ Chandigarh Call Girls ☎️99158-51334☎️ Escort service in Chandigarh ☎️ Chan...❤️ Chandigarh Call Girls ☎️99158-51334☎️ Escort service in Chandigarh ☎️ Chan...
❤️ Chandigarh Call Girls ☎️99158-51334☎️ Escort service in Chandigarh ☎️ Chan...
 
❤️ Chandigarh Call Girls Service ☎️99158-51334☎️ Escort service in Chandigarh...
❤️ Chandigarh Call Girls Service ☎️99158-51334☎️ Escort service in Chandigarh...❤️ Chandigarh Call Girls Service ☎️99158-51334☎️ Escort service in Chandigarh...
❤️ Chandigarh Call Girls Service ☎️99158-51334☎️ Escort service in Chandigarh...
 
Pathways to Equality: The Role of Men and Women in Gender Equity
Pathways to Equality:          The Role of Men and Women in Gender EquityPathways to Equality:          The Role of Men and Women in Gender Equity
Pathways to Equality: The Role of Men and Women in Gender Equity
 
Goa Call Girl 931~602~0077 Call ✂️ Girl Service Vip Top Model Safe
Goa Call Girl  931~602~0077 Call ✂️ Girl Service Vip Top Model SafeGoa Call Girl  931~602~0077 Call ✂️ Girl Service Vip Top Model Safe
Goa Call Girl 931~602~0077 Call ✂️ Girl Service Vip Top Model Safe
 
Bobath Technique (Samrth Pareta) .ppt.pptx
Bobath Technique (Samrth Pareta) .ppt.pptxBobath Technique (Samrth Pareta) .ppt.pptx
Bobath Technique (Samrth Pareta) .ppt.pptx
 

Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Synergistics, Complex System Analysis and Simulation of Alive Supersystems for Best Management.

  • 1. Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Synergistics, Complex System Analysis and Simulation of Alive Supersystems for Best Management. Kshivets Oleg Surgery Department, Bagrationovsk Hospital, Bagrationovsk, Kaliningrad, Russia
  • 2. ABSTRACT OBJECTIVE: The survival of patients with local advanced of esophageal cancer (EC) takes several months. Radical operations are extremely complex and remain the prerogative of several best thoracoabdominal surgeons of the world. The search of optimal treatment plan for EC patients (ECP) with stage T3-4N0-2M0 was realized. We examined factors in terms of precise prediction of 5-year survival (5YS) of local advanced ECP after complete (R0) combined esophagogastrectomies (E). METHODS: We analyzed data of 313 consecutive ECP (age=56.2±9 years; tumor size=8.1±2.8 cm) radically operated and monitored in 1975-2024 (m=233, f=80; Lewis=122, Garlock=191, combined E with resection of trachea, bronchus, lung, aorta, VCS, pericardium, liver, pancreas, diaphragm, colon, splenectomy=170; only surgery-S=217, adjuvant chemoimmunoradiotherapy-AT=96: 5FU+thymalin/taktivin +radiotherapy 45-50Gy; T3=185, T4=128; N0=96, N1=38, N2=179, M0=313; G1=71, G2=57, G3=185; squamous=109, adenocarcinoma=194, mix=10. Variables selected for 5YS study were input levels of 45 blood parameters, sex, age, TNMG, cell type, tumor size. Survival curves were estimated by the Kaplan-Meier method. Differences in curves between groups of ECP were evaluated using a log-rank test. Multivariate Cox modeling, multi-factor clustering, discriminant analysis, structural equation modeling, Monte Carlo, bootstrap, synergetics simulation and neural networks computing were used to determine any significant dependence. RESULTS: Overall life span (LS) was 1243.6±1691.4 days and cumulative 5YS reached 29%, 10 years – 19.2%, 20 years – 13.3%. 55 ECP lived more than 5 years (LS=4199.4±2295.3 days), 25 – more than 10 years (LS=6256.3±1884.8 days). 186 ECP died because of EC (LS=605.1±289.9 days). AT significantly improved 5YS (56.8% vs. 22%) (P=0.0000). Cox modeling displayed that 5YS of ECP significantly depended on: Phase Transition N0-N12 in terms of synergetics, G1-3, histology, AT, age, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), ESS, prothrombin index, hemorrhage time, protein, residual nitrogen (P=0.000-0.033). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (2), healthy cells/CC (3), erythrocytes/CC (4), segmented neutrophils/CC (5), eosinophils/CC (6), monocytes/CC (7), stick neutrophils/CC (8), lymphocytes/CC (9), leucocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing. CONCLUSIONS: 5YS of local advanced ECP after combined radical procedures significantly depended on: tumor characteristics, blood cell circuit, cell ratio factors, biochemical factors, hemostasis system, anthropometric data and adjuvant treatment. Optimal strategies for local advanced ECP are: 1) availability of very experienced thoracoabdominal surgeons because of complexity radical procedures; 2) aggressive en block surgery and adequate lymph node dissection for completeness; 3) precise prediction; 4) AT for ECP with unfavorable prognosis.
  • 3. Data: • Males…………………………………………………...233 • Females………..……………………………................80 • Age=56.2±9 years • Tumor Size=8.1±2.8 cm • Only Surgery.……………………………………........217 • Adjuvant Chemoimmunoradiotherapy • (5FU+thymalin/taktivin, 5-6 cycles+ Radiotherapy • 45-50Gy)………………………....................................96
  • 4. :Radical Procedures • Esophagogastrectomies Lewis (R0)…………………122 • Esophagogastrectomies Garlock (R0)………...........191 • Combined Esophagogastrectomies with Resection • of Pancreas, Liver, Trachea, Lung, Aorta, Vena • Cava Superior, Colon Transversum, Diaphragm, Pericardium, Splenectomy (R0)……………...............170 • 2-Field Lymphadenectomy…………………………….186 • 3-Field Lymphadenectomy.………………………….…127
  • 5. Staging: • T3……186 N0..…...96 G1………….71 • T4……128 N1….....38 G2………….57 • M0…..313 N2…....179 G3…………185 • Adenocarcinoma…………………………….194 • Squamos Cell Carcinoma…………………..110 • Mix………………….....…………………...........10
  • 6. Survival Rate: • Alive………………………………………......105 (33.5%) • 5-Year Survivors…………..…………..……..55 (17.6%) • 10-Year Survivors…………………………....25 (8%) • Losses………………………………………..186 (59.4%) • General Life Span=1243.6±1691.4 days • For 5-Year Survivors=4199.4±2295.3 days • For 10-Year Survivors=6256.3±1884.8 days • For Losses=605.1±289.9 days • Cumulative 5-Year Survival……………………….29% • Cumulative 10-Year Survival…………………......19.2% • Cumulative 20-Year Survival…………………......13.3%
  • 7. General Esophageal Cancer Patients (T3-4) Survival after Complete Esophagogastrectomies (Kaplan-Meier) (n=313): Survival Function 5YS=29%; 10YS=19.2%; 20YS=13.3% Complete Censored -5 0 5 10 15 20 25 30 35 Years after Esophagogastrectomies 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 Cumulative Proportion Surviving
  • 8. Results of Univariate Analysis of Phase Transition N0—N1-2 in Prediction of Esophageal Cancer Patients (T3-4) Survival (n=313): Cumulative Proportion Surviving (Kaplan-Meier) P=0.00354 Complete Censored 0 5 10 15 20 25 30 35 Years after Esophagogastrectomies 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving N0 N1-2
  • 9. Results of Univariate Analysis of Localization (Cardioesophageal vs. Esophageal) in Prediction of Esophageal Cancer Patients (T3-4) Survival (n=313): Cumulative Proportion Surviving (Kaplan-Meier) P=0.00109 Complete Censored 0 5 10 15 20 25 30 35 Years after Esophagogasrectomies -0.1 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving Esophageal Cancer Patients Cardioesophageal Cancer Patients
  • 10. Results of Univariate Analysis of Adjuvant Treatment (Adjuvant Chemoimmunoradiotherapy vs Surgery along) in Prediction of Esophageal Cancer Patients (T3-4) Survival (n=313): Cumulative Proportion Surviving (Kaplan-Meier) P=0.0000 Complete Censored 0 5 10 15 20 25 30 35 Years after Esophagogastrectomies -0.1 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving only Surgery Adjuvant Chemoimmunoradiotherapy
  • 11. Results of Cox Regression Modeling in Prediction of Esophageal Cancer Patients (T3-4) Survival after Complete Esophagogastrectomies (n=313): Cox Regression, ECP (T3-4N0-2), n=313 Parameter Estimate Standard Error Chi-square P value 95% Lower CL 95% Upper CL Eosinophils (%) 1.450 0.63707 5.17929 0.022858 0.201 2.698 Stick Neutrophils (%) 1.594 0.64188 6.16669 0.013018 0.336 2.852 Segmented Neutrophils (%) 1.616 0.63118 6.55406 0.010465 0.379 2.853 Lymphocytes (%) 1.640 0.63515 6.66400 0.009838 0.395 2.884 Monocytes (%) 1.717 0.64700 7.04410 0.007953 0.449 2.985 ESS -0.017 0.00751 5.03756 0.024803 -0.032 -0.002 Hemorrhage Time 0.001 0.00047 4.52166 0.033468 0.000 0.002 Residual Nitrogen 0.058 0.01241 22.03938 0.000003 0.034 0.083 Protein 0.032 0.01054 8.96255 0.002756 0.011 0.052 Prothrombin Index 0.038 0.00802 22.68268 0.000002 0.022 0.054 Phase Transition N0---N12 0.513 0.19200 7.13876 0.007544 0.137 0.889 Age 0.031 0.01019 9.40805 0.002160 0.011 0.051 Histology -0.444 0.15086 8.65327 0.003265 -0.739 -0.148 G1-3 0.282 0.10138 7.76029 0.005341 0.084 0.481 Leucocytes (tot) 22.981 4.89333 22.05549 0.000003 13.390 32.571 Eosinophils (tot) -22.335 4.85003 21.20792 0.000004 -31.841 -12.829 Stick Neutrophils (tot) -22.207 4.86970 20.79526 0.000005 -31.751 -12.662 Lymphocytes (tot) -23.049 4.93130 21.84678 0.000003 -32.714 -13.384 Segmented Neutrophils (tot) -23.024 4.88779 22.18959 0.000002 -32.604 -13.444 Monocytes (tot) -23.043 4.86741 22.41275 0.000002 -32.583 -13.503 Leucocytes/Cancer Cells -157.315 28.43656 30.60461 0.000000 -213.050 -101.581 Eosinophils/Cancer Cells 156.586 28.69089 29.78630 0.000000 100.353 212.819 Segmented Neutrophils/Cancer Cells 157.829 28.43487 30.80849 0.000000 102.098 213.560 Stick Neutrophils/Cancer Cells 153.093 28.44108 28.97477 0.000000 97.350 208.837 Lymphocytes/Cancer Cells 156.884 28.52403 30.25085 0.000000 100.978 212.790 Monocytes/Cancer Cells 155.948 28.15775 30.67366 0.000000 100.760 211.136 Esophageal/Cardioesophageal Cancer 0.440 0.17284 6.47954 0.010912 0.101 0.779 Adjuvant Chemoimmunoradiotherapy -0.874 0.21985 15.81752 0.000070 -1.305 -0.4435
  • 12. Results of Neural Networks and Monte Carlo Computing in Prediction of Esophageal Cancer Patients (T3-4) Survival after Complete Esophagogastrectomies (n=241): Corect Classification Rate=100% Error=0.000 Area under ROC Curve=1.000 Neural Networks: Baseline Error=0.000 Area under ROC Curve=1.000; Correct Classification Rate=100%; n=241 Rank Sensitivity Phase Transition N0---N12 1 701 Eosinophils/Cancer Cells 2 491 Stick Neutrophils/Cancer Cells 3 269 Healthy Cells/Cancer Cells 4 176 Erythrocytes/Cancer Cells 5 175 Monocytes/Cancer Cells 6 151 Lymphocytes/Cancer Cells 7 124 Thrombocytes/Cancer Cells 8 100 Segmented Neutrophils/Cancer Cells 9 30 Leucocytes/Cancer Cells 10 24
  • 13. Results of Bootstrap Simulation in Prediction of Esophageal Cancer Patients Survival (T3-4) after Complete Esophagogastrectomies (n=241): Bootstrap Simulation: Number of Samples=3333 Rank Kendall Tau P< Hemorrhage Time 1 -0.171 0.05 Blood Chlorides 2 0.171 0.05 Esophageal/Cardioesophageal Cancer 3 -0.151 0.05 Prothrombin Index 4 -0.146 0.05 Phase Transition N0---N12 5 -0.144 0.05 Protein 6 -0.142 0.05
  • 14. Results of Kohonen Self-Organizing Neural Networks Computing in Prediction of Esophageal Cancer Patients (T3-4) Survival after Complete Esophagogastrectomies (n=241):
  • 16. Prognostic Equation Models of Esophageal Cancer Patients (T3-4) Survival after Complete Esophagogastrectomies (n=241):
  • 17. Prognostic Equation Models of Esophageal Cancer Patients (T3-4) Survival after Complete Esophagogastrectomies (n=241):
  • 18. Prognostic Equation Models of Esophageal Cancer Patients (T3-4) Survival after Complete Esophagogastrectomies (n=241):
  • 19. Prognostic Equation Models of Esophageal Cancer Patients (T3-4) Survival after Complete Esophagogastrectomies (n=241):
  • 20. SEPATH Modeling in Prediction of Esophageal Cancer Patients (T3-4) Survival after Complete Esophagogastrectomies (n=241):
  • 21. 5-year survival of ECP after radical procedures significantly depended on: 1) PT N0--N12; 2) Cell Ratio Factors; 3) Blood Cell Circuit; 4) Biochemical Factors; 5) Hemostasis System; 6) Adjuvant Treatment; 7) EC Characteristics; 8) EC Cell Dynamics; 9) Tumor Localization; 10) Anthropometric Data; 11) Surgery Type. Conclusion:
  • 22. Optimal treatment strategies for local advanced ECP (T3-4) are: 1) Availability of Sufficient Quantity of Very Experienced Thoracoabdominal Surgeons because of Extreme Complexity of Radical Procedures; 2) Aggressive en block Combined Surgery and Adequate Lymph Node Dissection for Completeness; 3) Precise Prediction; 4) Adjuvant Chemoimmunoradiotherapy for ECP with Unfavorable Prognosis. Conclusion:
  • 23. Address: Oleg Kshivets, M.D.,Ph.D. Consultant Thoracic, Abdominal, General Surgeon & Surgical Oncologist • e-mail: okshivets@yahoo.com • skype: okshivets • http: //www.ctsnet.org/home/okshivets